NCT03757130 - Multiple Ascending Dose Study of AMG 598 in Adults With Obesity | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

December 16, 2019

Study Completion Date

December 16, 2019

Conditions

Obesity

Interventions

DRUG

AMG 598

AMG 598 administered by subcutaneous injection

DRUG

Placebo

Placebo matching to AMG 598 administered by subcutaneous injection

DRUG

Liraglutide

Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.

Trial Locations (4)

33143

QPS Miami Research Associates, South Miami

35235

William D Summers MD LLC, Birmingham

75230

Dallas Diabetes and Endocrine Center, Dallas

92780

Orange County Research Center, Tustin